NCT03851861 (MED) is a NA clinical trial of Mediterranean Diet in Parkinson Disease, sponsored by University of Florida.

Who is sponsoring NCT03851861?

NCT03851861 is sponsored by University of Florida.

What drugs are being tested in NCT03851861?

Interventions in NCT03851861: Mediterranean Diet.

What condition does NCT03851861 study?

NCT03851861 studies Parkinson Disease.

Is NCT03851861 still recruiting?

NCT03851861 is currently completed. Last updated 4 May 2021.

Last reviewed 2021-05-04 · How we verify

NCT03851861: MED

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dietary Intervention and Gastrointestinal Function in Patients With Parkinson's Disease

Completed NA Last updated 4 May 2021

What this trial tests

NA trial testing Mediterranean Diet in Parkinson Disease in 8 participants. Completed in 3 May 2021.

Timeline

15 April 2019

Primary endpoint
13 November 2019

3 May 2021

Quick facts

Lead sponsor	University of Florida
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	8
Start date	15 April 2019
Primary completion	13 November 2019
Estimated completion	3 May 2021
Sites	1 location across United States

Drugs / interventions tested

Mediterranean Diet

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

University of Florida

Who can join

Adults 21 to 85, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this prospective, intervention study, participants with diagnosed Parkinson's disease will be instructed to follow a Mediterranean diet for five weeks. Gut permeability will be assessed using food-grade sugar molecules. Participants will provide urine and stool samples to assess gut permeability and microbial communities.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Mediterranean Diet Adherence in People With Parkinson's Disease Reduces Constipation Symptoms and Changes Fecal Microbiota After a 5-Week Single-Arm Pilot Study.
Rusch C, Beke M, Tucciarone L, Nieves C, et al · · 2021 · cited 45× · PMID 35002935 · DOI 10.3389/fneur.2021.794640
"Janus-Faced" α-Synuclein: Role in Parkinson's Disease.
Ray B, Mahalakshmi AM, Tuladhar S, Bhat A, et al · · 2021 · cited 7× · PMID 34124057 · DOI 10.3389/fcell.2021.673395
Management and Prevention of Neurodegenerative Disorders: Can Antioxidant-Rich Dietary Interventions Help?
Nagpal D, Nema S, Nagpal S, Pandey MM, et al · · 2025 · cited 2× · PMID 41008984 · DOI 10.3390/antiox14091078
The gut microbiota influences neurodegenerative diseases through the gut-brain axis: molecular mechanisms and effects on immune function.
Yang J, Song X, Yan S, Li Q, et al · · 2025 · PMID 41601624 · DOI 10.3389/fimmu.2025.1739329

Verify or expand the search:

Other trials of Mediterranean Diet

Trials testing the same drug.

NCT07446777 — FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Pre · NA · not yet recruiting
NCT07442799 — Efficacy of a Culturally-adapted Mediterranean Diet Intervention on Depression in Relation to the Gut Microbiome · NA · not yet recruiting
NCT04772651 — Mediterranean Diet and the Microbiota Gut Brain Axis in Major Depression · NA · not yet recruiting
NCT07189637 — The Combined Effect of the Mediterranean Diet and Intermittent Fasting on Hypertension · NA · not yet recruiting
NCT07200934 — Effect of Adding TENS to Mediterranean Diet on Appetite and Liver Enzymes in Nonalcoholic Fatty Liver Patients · NA · not yet recruiting

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other University of Florida trials

Trials by the same sponsor.

NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03851861 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Florida
Last refreshed: 4 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03851861.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing